33.7 C
New York
Friday, June 12, 2026

Tag: regulatory approval

newssourceFORcompanyinformationcontent1marketreleases

HLS Therapeutics Announces Q2 2025 Financial Results

Adjusted EBITDA grew 21% in Q2 and 29% year-to-date Cash from operations grew 83% in Q2 and 147% year-to-dateMade principal repayments on the Company's...

Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic

Ad hoc announcement pursuant to Art. 53 LR

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

FRONTERA ANNOUNCES SECOND QUARTER 2025 RESULTS

Recorded $455.2 million in Net Loss Mainly due to Non-Cash Impairment Charges Related to its Interest in the Corentyne License and Ecuadorian Assets Increased Total...

Shilpa Medicare’s NorUDCA Makes History as First Approved NAFLD Therapy Worldwide

Shilpa Medicare emerges as the global pioneer to receive approval for NorUDCA, offering new hope to over a billion people affected by Non-Alcoholic Fatty...

VitalHub Corp. Announces $65 Million Bought Deal Public Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Aug. 13, 2025 /CNW/ - VitalHub Corp. (the "Company" or...

Applied Therapeutics Reports Second Quarter 2025 Financial Results

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

TransferMate submits application for Bahrain license, as it expands its footprint in the Middle East

DUBLIN, Aug. 13, 2025 /PRNewswire/ -- TransferMate, the world's leading provider of embedded B2B payments infrastructure as a service (IaaS), has today announced it...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.

Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

Terrestrial Energy Selected for DOE Office of Nuclear Energy Advanced Reactor Pilot Program for Accelerated Development

Advanced Reactor Pilot Program launched by DOE to expedite authorization and commercialization of advanced nuclear reactor designs

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsRegulatory approval

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers